Exenatide

Most common side effect, especially during the first 1-2 weeks of treatment. Usually resolves with continued use as the body adapts. Occurs in 40-50% of users. Manage by taking doses with food, staying hydrated, and eating small, frequent meals. Antiemetics (e.g., ginger, vitamin B6) may help.

Occurs in 5-10% of users, typically early in treatment. If severe or persistent, contact a healthcare provider. May indicate need for dose adjustment or temporary discontinuation.

Occurs in 5-10% of users. Usually self-resolving within days to weeks. Manage with adequate hydration and dietary fiber. Avoid high-fat foods which may exacerbate symptoms.

Occurs in 5-10% of users. Manage with increased water intake, dietary fiber, and physical activity. Stool softeners may be used if needed.

Occurs in 5-10% of users. Usually mild and self-resolving. Over-the-counter analgesics (acetaminophen, ibuprofen) may be used if needed.

Occurs in 5-10% of users, particularly if blood glucose drops rapidly. Ensure adequate carbohydrate intake and monitor blood glucose regularly. Rise slowly from sitting or lying positions.

Risk is increased when exenatide is combined with insulin or sulfonylureas. Symptoms include tremor, sweating, palpitations, anxiety, confusion, and loss of consciousness. Always carry fast-acting carbohydrates (glucose tablets, juice). Requires immediate medical attention if severe. Dose adjustment of concurrent medications may be necessary.

Redness, swelling, or itching at injection site occurs in 5-10% of users. Manage by rotating injection sites, using proper injection technique, and allowing the solution to reach room temperature before injection. Topical antihistamines may help itching.

Occurs with repeated injections in the same area. Prevent by rotating injection sites systematically and maintaining at least 1 inch between injection points. This is a cosmetic concern but can affect absorption if severe.

Rare but serious adverse event reported in clinical trials and post-marketing surveillance. Symptoms include severe upper abdominal pain, back pain, nausea, and vomiting. Requires immediate emergency medical evaluation. Discontinue exenatide immediately if pancreatitis is suspected. History of pancreatitis is a relative contraindication.

Animal studies showed dose-dependent thyroid C-cell proliferation and medullary thyroid carcinoma at high doses. Clinical relevance in humans is unclear, but exenatide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).

Rare cases reported, particularly in patients with pre-existing renal impairment or severe dehydration. Monitor renal function and ensure adequate hydration. Use with caution in patients with eGFR <30 mL/min/1.73m².

Rare but serious. Symptoms include rash, urticaria, angioedema, dyspnea, and anaphylaxis. Requires immediate emergency medical attention. Discontinue exenatide immediately if allergic reaction occurs.

Exenatide slows gastric emptying as part of its mechanism, but severe gastroparesis is rare. Symptoms include persistent nausea, vomiting, and abdominal bloating. Monitor for worsening GI symptoms; dose adjustment or discontinuation may be necessary.

Intentional effect of exenatide that contributes to weight loss. However, excessive appetite suppression may lead to inadequate caloric intake. Ensure balanced nutrition and monitor for signs of malnutrition.